AR052880A1 - Metodo para tratar dolor visceral - Google Patents

Metodo para tratar dolor visceral

Info

Publication number
AR052880A1
AR052880A1 ARP060100177A ARP060100177A AR052880A1 AR 052880 A1 AR052880 A1 AR 052880A1 AR P060100177 A ARP060100177 A AR P060100177A AR P060100177 A ARP060100177 A AR P060100177A AR 052880 A1 AR052880 A1 AR 052880A1
Authority
AR
Argentina
Prior art keywords
visceral pain
treat visceral
administering
oxycodone
dose
Prior art date
Application number
ARP060100177A
Other languages
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052880(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR052880A1 publication Critical patent/AR052880A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

Es posible tratar efectivamente el dolor visceral moderado a severo administrando medicamentos analgésicos que contienen el opioide oxicodona o sales farmacéuticamente aceptables de la misma. El dolor visceral y especialmente el dolor visceral agudo (esto es, no cronico) puede tratarse efectivamente mediante la administracion de oxicodona en una dosis inferior a la dosis correspondiente de otros opioides tales como la morfina.
ARP060100177A 2005-01-18 2006-01-18 Metodo para tratar dolor visceral AR052880A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18

Publications (1)

Publication Number Publication Date
AR052880A1 true AR052880A1 (es) 2007-04-11

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100177A AR052880A1 (es) 2005-01-18 2006-01-18 Metodo para tratar dolor visceral

Country Status (32)

Country Link
US (2) US20080200493A1 (es)
EP (1) EP1838318B1 (es)
JP (1) JP5049139B2 (es)
KR (10) KR20080106991A (es)
CN (1) CN101106996B (es)
AP (1) AP2249A (es)
AR (1) AR052880A1 (es)
AT (2) ATE446092T1 (es)
AU (1) AU2006207498B2 (es)
BR (1) BRPI0606247A2 (es)
CA (1) CA2595043C (es)
CY (1) CY1109660T1 (es)
DE (2) DE602006009899D1 (es)
DK (2) DK1838318T3 (es)
EA (1) EA013544B1 (es)
ES (1) ES2333901T3 (es)
HK (1) HK1107933A1 (es)
HR (1) HRP20090679T1 (es)
IL (1) IL184530A (es)
ME (1) ME01066B (es)
MX (1) MX2007007207A (es)
MY (1) MY144471A (es)
NO (1) NO338968B1 (es)
NZ (1) NZ555852A (es)
PL (1) PL1838318T3 (es)
PT (1) PT1838318E (es)
RS (1) RS51069B (es)
SI (1) SI1838318T1 (es)
TW (1) TWI432196B (es)
UA (1) UA85471C2 (es)
WO (1) WO2006077212A1 (es)
ZA (1) ZA200705231B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2380592T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh Antagonist antibody directed to calcitonin gene related peptide
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
KR101519192B1 (ko) * 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
EP2709663B1 (en) 2011-05-20 2019-03-20 AlderBio Holdings LLC Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EA039905B1 (ru) 2011-05-20 2022-03-25 Х. Лундбек А/С Анти-cgrp антитела и их применение
BR112013029951B1 (pt) 2011-05-20 2020-10-20 Alderbio Holdings Llc composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2943551A1 (en) 2014-03-21 2015-09-24 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
BR112019005823A2 (pt) 2016-09-23 2019-06-25 Teva Pharmaceuticals Int Gmbh tratamento para enxaqueca refratária
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE AND RAPID TREATMENT OF HEADACHES USING ANTI-CGRP ANTIBODIES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EA000976B1 (ru) * 1996-03-25 2000-08-28 Эли Лилли Энд Компани Композиция для снятия боли и способ снятия боли
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
NO338968B1 (no) 2016-11-07
WO2006077212A1 (en) 2006-07-27
DK200700207U3 (da) 2007-09-28
HK1107933A1 (en) 2008-04-25
KR20230170811A (ko) 2023-12-19
KR20120089710A (ko) 2012-08-13
US9271974B2 (en) 2016-03-01
CN101106996B (zh) 2013-10-23
AP2249A (en) 2011-07-18
SI1838318T1 (sl) 2010-02-26
EP1838318B1 (en) 2009-10-21
MY144471A (en) 2011-09-30
KR20070100368A (ko) 2007-10-10
IL184530A (en) 2015-01-29
JP5049139B2 (ja) 2012-10-17
CA2595043A1 (en) 2006-07-27
IL184530A0 (en) 2007-10-31
TW200637554A (en) 2006-11-01
NO20074174L (no) 2007-10-17
EA200701541A1 (ru) 2008-02-28
US20150190393A1 (en) 2015-07-09
US20080200493A1 (en) 2008-08-21
DK1838318T3 (da) 2010-01-04
UA85471C2 (ru) 2009-01-26
AP2007004057A0 (en) 2007-08-31
DK200700207U1 (da) 2007-08-24
EA013544B1 (ru) 2010-06-30
HRP20090679T1 (hr) 2010-01-31
EP1838318A1 (en) 2007-10-03
AU2006207498A1 (en) 2006-07-27
NZ555852A (en) 2010-01-29
BRPI0606247A2 (pt) 2009-06-09
RS51069B (sr) 2010-10-31
ES2333901T3 (es) 2010-03-02
DE602006009899D1 (de) 2009-12-03
CA2595043C (en) 2013-11-19
PL1838318T3 (pl) 2010-03-31
AT9895U1 (de) 2008-05-15
TWI432196B (zh) 2014-04-01
KR20210131450A (ko) 2021-11-02
CN101106996A (zh) 2008-01-16
JP2008526927A (ja) 2008-07-24
KR20080106991A (ko) 2008-12-09
CY1109660T1 (el) 2014-08-13
KR20220165797A (ko) 2022-12-15
ME01066B (me) 2012-10-20
PT1838318E (pt) 2009-12-15
KR20140091782A (ko) 2014-07-22
DE202006019887U1 (de) 2007-07-26
ATE446092T1 (de) 2009-11-15
KR20190135557A (ko) 2019-12-06
KR20200128451A (ko) 2020-11-12
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
ZA200705231B (en) 2008-06-25
AU2006207498B2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AR052880A1 (es) Metodo para tratar dolor visceral
AR058598A1 (es) Administracion transdermica de meptazinol
AR086391A1 (es) Formas de dosificacion farmaceutica intranasales que comprenden naloxona
EA201300465A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
AR092820A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
HK1176318A1 (en) Injection device
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MX2009005798A (es) Recuperacion de apoplejia.
EA200870182A1 (ru) Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов
GEP20125526B (en) Drug active in neuropathic pain
WO2011109743A3 (en) Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
DE602004030048D1 (de) Ffizienz
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
MX2020007860A (es) Tratamientos combinados para crisis de opioides.
AR060394A1 (es) Composicion farmaceutica que comprende un analgesico y vitaminas
MX2016007370A (es) Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
ATE380550T1 (de) Synergistische kombination eines opiatanalgetikums und eines nsaid
AR069008A1 (es) Composicion farmaceutica para tratar un linfoma en un perro que comprende idarubicina, uso
TH85791A (th) วิธีการรักษาความเจ็บปวดอวัยวะภายใน
ATE468852T1 (de) Lofexidine zur intraspinalen anwendung

Legal Events

Date Code Title Description
FB Suspension of granting procedure